Home Your basket
• Does indermil glue improv...
   Price 5.50 €
• The ultra-low resistance ...
   Price 5.50 €
• Cervico facial lymphangio...
   Price 10.50 €
• Zenker’s diverticulum in ...
   Price 8.50 €
• Modified butterfly cartil...
   Price 10.50 €
• Supra and infra hyoid mid...
   Price 10.50 €
• Adaptation and validation...
   Price 10.50 €
• The input of autogenous g...
   Price 10.50 €
• Recurrent mandibular amel...
   Price 12.50 €
• Kikuchi-Fujimoto’s diseas...
   Price 10.50 €
• Training strategies of th...
   Price 8.50 €
• Validation of a clinical ...
   Price 10.50 €
• Phonatory threshold press...
   Price 10.50 €
• Salivary gland choristoma...
   Price 5.50 €
• Hearing aid : practical a...
   Price 8.50 €
• Total pharyngolayngectomy...
   Price 10.50 €
• Thyroid tuberculosis asso...
   Price 5.50 €
• Endoscopic medialization ...
   Price 8.50 €
• Recurrences of pleomorphi...
   Price 10.50 €
• Parapharyngeal tumours: M...
   Price 10.50 €
• Paraganglioma of the cere...
   Price 5.50 €
• Laryngeal paraganglioma m...
   Price 8.50 €
• Early PTH assay after tot...
   Price 10.50 €
• Merkel cell carcinoma of ...
   Price 8.50 €
• Unilateral laryngeal para...
   Price 10.50 €
• Sinonasal malignant schwa...
   Price 5.50 €
• Ethmoidal metastasis reve...
   Price 8.50 €
• Inferior turbinate hypert...
   Price 10.50 €
• Rhinophyma in a black afr...
   Price 5.50 €
• Metastatic angiosarcoma t...
   Price 5.50 €
• Allergic and pneumologic ...
   Price 8.50 €
• An original case of laryn...
   Price 8.50 €
• Aspects of voice quality ...
   Price 5.50 €

Total Order 285.50 €

contents
2019
   N# 1 |
2018
   N# 1 | 2 | 3 | 4 | 5 |
2017
   N# 1 | 2 | 3 | 4 | 5 |
2016
   N# 1 | 2 | 3 | 4 | 5 |
2015
   N# 1 | 2 | 3 | 4 | 5 |
2014
   N# 1 | 2 | 3 | 4 | 5 |
2013
   N# 1 | 2 | 3 | 4 | 5 |
2012
   N# 1 | 2 | 3 | 4 | 5 |
2011
   N# 1 | 2 | 3 | 4 | 5 |
2010
   N# 1 | 2 | 3 | 4 | 5 |
2009
   N# 1 | 2 | 3 | 4 | 5 |
2008
   N# 1 | 2 | 3 | 4 | 5 |
2007
   N# 1 | 2 | 3 | 4 | 5 |
2006
   N# 1 | 2 | 3 | 4 | 5 |
2005
   N# | 1 | 2 | 3 | 4 | 5 |
2004
   N# 1 | 2 | 3 | 4 | 5 |
2003
   N# 1 | 2 | 3 | 4 | 5 |
2002
   N# 1 | 2 | 3 | 4 | 5 |
2001
   N# 1 | 2 | 3 | 4 | 5 |
2000
   N# | 1 | 2 | 3 | 4 | 5 |
1999
   N# 1 | 2 | 3 | 4 | 5 |
1998
   N# 1 | 2 | 3 | 5 |
1997
   N# 1 | 2 | 3 | 4 | 5 |
1996
   N# 4 | 5 |

Click on the number of the review to see the content
Teaching bulletin CME
List of all teaching bulletins CME.
Editor reading committee
Editor reading committee.
To publish...
Instructions for authors
Archives Press and Books
Select of books and press articles.
Mailing list
News information letter.
Subscription prices


If you wish to adjust the size of the displayed characters, click in the high menu on "Your account" and choose the desired size.



  Contents > Previous page > Article detail print Order
o Issue N# 1 - 2005 o

RHINOLOGY

Treatments of hereditary hemorrhagic telangiectasia of the nasal mucosa


Authors : E. Babin, M. Borsik, S. Braccard, L. Crampette, V. Darrouzet, F. Faure, J. P. Fontanel, E. Houdart, R. Jankowski, G. Le Clech, L. Malvezzi, S. Morini, S. Perie, J. Perret, J. C. Pignat, F. Portier, E. Serrano, H. Plauchu (France - Italie)

Ref. : Rev Laryngol Otol Rhinol. 2005;126,1:43-48.

Article published in french
Downloadable PDF document french



Summary : Hereditary Hemorrhagic Telangiectasia is a systemic autosomal dominant disorder involving blood vessels. The most common symptom is reccurent epistaxis. The treatments of these epistaxis are numerous but such treatments are often symptomatic and their effects are often not sustained. Some of these treatments may be complicated by visceral vascular malformations. The aim of this study is to propose a treatment plan for these patients with hierarchical organisation of therapeutic options taking into account of their previous therapy. Method: H. Plauchu organized in Paris, december 2002 a meeting with any medical specialists of this diesease. They have analysed variety of therapies that have been proposed for epistaxis control in Hereditary Haemorrhagic Télangiectasia. Results: Most common use packing of nasal fossa and then hyperselective embolization of the internal maxillary and facial arteries for severe epistaxis. For chronic epistaxis, best treatment use sclerotics products (Ethibloc®) and laser. After discussion, primary embolization could be useful to reduce vascularization of nasal fossa. Conclusion: Treatment of epistaxis in Hereditary Haemorrhagic Telangiectasia could increase in few years. Use of an index card of for epistaxis in the disease of Rendu-Osler could help to find treatment of choice.

Price : 10.50 €      order
|


Subscribe online - Pay by credit card!


© Copyright 1999-2024 - Revue de Laryngologie   Réalisation - Hébergement ELIDEE